Kura Oncology Inc (NASDAQ:KURA)

18.02
Delayed Data
As of Oct 15
 0.00 / 0.00%
Today’s Change
15.12
Today|||52-Week Range
43.00
-44.83%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$1.2B

Company Description

Kura Oncology, Inc. operates as a clinical-stage biopharmaceutical company which engages in the research and development of medicines for the treatment of cancer. Its pipeline includes Tipifarnib which is a Farnesyl transferase inhibitor for HRAS Mutant Solid Tumors, Chronic Myelomonocytic Leukemia; KO-947 which is an ERK inhibitor for MAPK Pathway Tumors; and KO-539 which is a Menin MLL inhibitor for acute leukemias. The company was founded by Troy E. Wilson, Yi Liu, Pingda Ren and Antonio Gualberto on August 22, 2014 and is headquartered in La Jolla, CA.

Contact Information

Kura Oncology, Inc.
12730 High Bluff Drive
San Diego California 92130
P:(858) 500-8800
Investor Relations:

Employees

Shareholders

Other institutional52.73%
Mutual fund holders45.55%
Individual stakeholders12.66%

Top Executives

Troy E. WilsonChairman, President & Chief Executive Officer
Kathleen FordChief Operating Officer
Marc Edward GrassoChief Financial & Business Officer
Stephen DaleChief Medical Officer
Mollie LeoniVice President-Clinical Development